Cargando…
国产达沙替尼二线治疗慢性髓性白血病慢性期患者的疗效和安全性分析
OBJECTIVE: To investigate the efficiency and safety of domestic tyrosine kinase inhibitor (TKI) dasatinib (Yinishu) as second-line treatment for patients with chronic myeloid leukemia in chronic phase (CML-CP). METHODS: A retrospective analysis of clinical data of CML-CP patients who received domest...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342660/ https://www.ncbi.nlm.nih.gov/pubmed/30831623 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.02.002 |
Ejemplares similares
-
国产达沙替尼治疗新诊断的慢性髓性白血病慢性期患者疗效及安全性分析
Publicado: (2020) -
国产达沙替尼二线治疗慢性髓性白血病早期分子学反应的预后意义
Publicado: (2019) -
国产达沙替尼治疗慢性髓性白血病慢性期患者的药代动力学研究
Publicado: (2016) -
尼洛替尼和达沙替尼作为二三线药物治疗慢性髓性白血病慢性期和加速期患者的疗效及影响因素分析
Publicado: (2020) -
尼洛替尼一线、二线治疗慢性髓性白血病慢性期分子学反应的对比研究
Publicado: (2019)